Lycopene Prevents DEHP-Induced Liver Lipid Metabolism Disorder by Inhibiting the HIF-1α-Induced PPARα/PPARγ/FXR/LXR System

J Agric Food Chem. 2020 Oct 14;68(41):11468-11479. doi: 10.1021/acs.jafc.0c05077. Epub 2020 Oct 5.

Abstract

Di(2-ethylhexyl) phthalate (DEHP) is a widespread pollutant that badly affects animals and human health. Lycopene (LYC) has been used as a dietary supplement that has effective antioxidant and antiobesity functions. The present goal was to understand the molecular mechanisms of LYC preventing DEHP-induced lipid metabolism of the liver. The mice were intragastrically administered with LYC (5 mg/kg) and/or DEHP (500 mg/kg or 1000 mg/kg). Here, we found that LYC attenuated DEHP-caused hepatic histopathological lesions including steatosis. Hematological and biochemical analyses revealed that LYC ameliorated DEHP-caused liver function and lipid metabolism disorders. DEHP caused lipid metabolism disorders via activating the peroxisome proliferator activated receptor α/γ (PPARα/γ) signal transducer and Farnesoid X receptor (FXR)/liver X receptor (LXR) signaling pathway. As a major regulator of lipid metabolism, hypoxia-inducible factor-1α (HIF-1α) system was elevated with increased fatty degeneration under DEHP exposure. However, LYC could decrease the levels of HIF-1α/PPARα/PPARγ/FXR/LXR signaling pathway-related factors. Our research indicated that LYC could prevent DEHP-induced lipid metabolism disorders via inhibiting the HIF-1α-mediated PPARα/PPARγ/FXR/LXR system. This study may provide a possible molecular mechanism for fatty liver induced by DEHP.

Keywords: di(2-ethylhexyl) phthalate; hypoxia-inducible factor-1α; lipid metabolism; lycopene.

MeSH terms

  • Animals
  • Antioxidants
  • Diethylhexyl Phthalate / adverse effects
  • Humans
  • Hypoxia-Inducible Factor 1, alpha Subunit / genetics
  • Hypoxia-Inducible Factor 1, alpha Subunit / metabolism*
  • Lipid Metabolism / drug effects
  • Lipid Metabolism Disorders / chemically induced
  • Lipid Metabolism Disorders / drug therapy*
  • Lipid Metabolism Disorders / genetics
  • Lipid Metabolism Disorders / metabolism
  • Liver Diseases / drug therapy*
  • Liver Diseases / etiology
  • Liver Diseases / genetics
  • Liver Diseases / metabolism
  • Liver X Receptors / genetics
  • Liver X Receptors / metabolism*
  • Lycopene / administration & dosage*
  • Male
  • Mice
  • Mice, Inbred ICR
  • PPAR alpha / genetics
  • PPAR alpha / metabolism*
  • PPAR gamma / genetics
  • PPAR gamma / metabolism*
  • Receptors, Cytoplasmic and Nuclear / genetics
  • Receptors, Cytoplasmic and Nuclear / metabolism*
  • Signal Transduction

Substances

  • Antioxidants
  • Hypoxia-Inducible Factor 1, alpha Subunit
  • Liver X Receptors
  • PPAR alpha
  • PPAR gamma
  • Receptors, Cytoplasmic and Nuclear
  • farnesoid X-activated receptor
  • Diethylhexyl Phthalate
  • Lycopene